Factors associated with readmission after long-term administration of tolvaptan in patients with congestive heart failure.

Yamashita, Shoko; Takenaka, Miki; Ohbayashi, Masayuki; Kohyama, Noriko; Kurihara, Tatsuya; Sunaga, Tomiko; Ishiguro, Hisaaki; Kogo, Mari

Yamashita, Shoko; Takenaka, Miki; Ohbayashi, Masayuki; Kohyama, Noriko; Kurihara, Tatsuya; Sunaga, Tomiko; Ishiguro, Hisaaki; Kogo, Mari.

Affiliation

Yamashita S; Department of Pharmacy, New Tokyo Hospital, Chiba; Division of Pharmacotherapeutics, Department of Clinical Pharmacy, School of Pharmacy, Showa University, Tokyo, Japan.
Takenaka M; Division of Pharmacotherapeutics, Department of Clinical Pharmacy, School of Pharmacy, Showa University, Tokyo, Japan.
Ohbayashi M; Division of Pharmacotherapeutics, Department of Clinical Pharmacy, School of Pharmacy, Showa University, Tokyo, Japan.
Kohyama N; Division of Pharmacotherapeutics, Department of Clinical Pharmacy, School of Pharmacy, Showa University, Tokyo, Japan.
Kurihara T; Division of Natural Medicine and Therapeutics, Department of Clinical Pharmacy, School of Pharmacy, Showa University, Tokyo, Japan.
Sunaga T; Department of Hospital Pharmaceutics, School of Pharmacy, Showa University, Tokyo, Japan.
Ishiguro H; Department of Cardiology, New Tokyo Hospital, Chiba; Department of Cardiology, Ichinomiya Municipal Hospital, Aichi, Japan.
Kogo M; Division of Pharmacotherapeutics, Department of Clinical Pharmacy, School of Pharmacy, Showa University, Tokyo, Japan.

Singapore Med J ; 2023 Feb 06.

Article in En | MEDLINE | ID: mdl-36751847

Key words

Heart failure; long-term administration; readmission; tolvaptan

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Observational_studies / Prognostic_studies / Risk_factors_studies Language: En Journal: Singapore Med J Year: 2023 Document type: Article

Fulltext

XML

PubMed Links

Search on Google